28 September 2020 in Journal of Medical Virology
DPDiana L. Pacheco‐Olvera
+6
23 August 2022 in Archives of Gynecology and Obstetrics
15 September 2025 in bioRxiv
Modeling human epithelial diseases and developing cell-based therapies require robust methods to expand and manipulate epithelial stem and progenitor cells in vitro . Basal stem/progenitor cells from stratified epithelia can be expanded in 3T3-J2 fibroblast feeder cell co-culture systems, and the addition of the ROCK inhibitor Y-27632 enhances proliferation and culture longevity, a phenomenon described as ‘conditional reprogramming’. Here, we present a method incorporating the small molecule WS6 to further improve the proliferation and lifespan of cultured epithelial cells from multiple tissues, including airway, skin, and thymus. Cells maintained in this medium (‘EpMED’; FAD+Y+WS6) retain basal stem/progenitor cell identity and function, including the capacity to differentiate. We demonstrate their capacity to engraft in vivo in a tracheal transplantation model. In a second application, we generate clonal CRISPR-Cas9 genome edited nasal cultures, introducing targeted knockouts of DNAH5 or DNAI2 to create primary ciliary dyskinesia disease models. We anticipate that our method will have broad applications in epithelial cell biology, disease modeling, and regenerative medicine, while reducing reliance on immortalized or cancer cell lines and animal experimentation.
25 April 2024 in Research Square
PLPatricia Loranca-Moreno
MMMaricruz Dañino- Morales
JNJael Vergara-Lope Nuñez
+5
Objective: This study compares the clinical improvement of genitourinary syndrome of menopause (GSM) and the capacity of vaginal biorevitalization between the gold standard treatment based on local hormonal therapy with estrogens (ES-based therapy) versus local therapy based on salmon polydeoxyribonucleotides (PDRNs-based therapy). Study design: Double blinded randomized clinical trial. The colposcopist and pathologist were blinded about which patient received one treatment or another. We randomly assigned 106 postmenopausal women (aged 38-77) with GSM. The control group (n=49) received ES-based therapy with bovine estrogen cream three times weekly. The treatment group (n=57) received vaginal suppositories from PDRNs only for six days every night during the first week. Main outcome measures: the severity of sexual and urinary problems, and the vaginal dryness using the Menopause Rating Scale (MRS). Moreover, alteration in vaginal pH and the atrophy of vaginal epithelium. Results: At 3 months of follow-up, the PDRNs-based therapy group presented a significantly decreased in the probability of presenting moderate-to-severe symptoms for sexual problems (OR= 0.07, CI 0.16-0.33, p<0.001), urinary problems (OR= 0.10, CI 002-0.50, p=0.004), vaginal dryness (OR= 0.17, CI 0.03-0.84, p=0.03), altered vaginal pH (pH>5) (OR= 0.20, CI 0.0.09-0.47, p<0.001) and atrophy of vaginal epithelium (OR= 0.02 CI 0.006-0.09, p<0.001) compared with the ES group. We also found a significant augmentation of intermediate cells in PDRNs-treated group (p=0.001). Conclusion: Our data suggest that PDRNs-based local therapy can biorevitalize the vagina and improve GSM in a clinically significant manner compared to the gold standard treatment with ES-based therapy (NCT05464654).